

## PATENT COOPERATION TREATY

PCT

10/030.808

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 03 APR 2002

Applicant's or agent's file reference DC-0134	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/18775	International filing date (day/month/year) 11 July 2000 (11.07.2000)	Priority date (day/month/year) 12 July 1999 (12.07.1999)
International Patent Classification (IPC) or national classification and IPC IPC(7): C12N 9/48; C12Q 1/37; C07K 1/00; A61K 38/00 and US Cl.: 435/212, 23, 24; 530/350; 514/1, 12		
Applicant THE TRUSTEES OF DARTMOUTH COLLEGE		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets, including this cover sheet.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I  Basis of the report
- II  Priority
- III  Non-establishment of report with regard to novelty, inventive step and industrial applicability
- IV  Lack of unity of invention
- V  Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI  Certain documents cited
- VII  Certain defects in the international application
- VIII  Certain observations on the international application

Date of submission of the demand 01 February 2001 (01.02.2001)	Date of completion of this report 11 March 2002 (11.03.2002)
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	Authorized officer Gabriele E. BUGAISKY Telephone No. 708 308-0196

Form PCT/IPEA/409 (cover sheet)(July 1998)

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International Application No.

PCT/US00/18775

**I. Basis of the report**

## 1. With regard to the elements of the international application:\*

 the international application as originally filed. the description:

pages 1-24 as originally filed

pages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_ the claims:

pages 25-28, as originally filed

pages NONE, as amended (together with any statement) under Article 19pages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_ the drawings:

pages 1-3, as originally filed

pages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_ the sequence listing part of the description:

pages 1-4, as originally filed

pages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_

## 2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

 the language of a translation furnished for the purposes of international search (under Rule 23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

## 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

 contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4.  The amendments have resulted in the cancellation of: the description, pages NONE the claims, Nos. NONE the drawings, sheets/fig NONE5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International Application No.  
PCT/US00/18775

## V: Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

## 1. STATEMENT

Novelty (N)	Claims 1-5,10 and 17-22	YES
	Claims 6-9 and 11-16	NO
Inventive Step (IS)	Claims 1-5,10 and 17-22	YES
	Claims 6-9 and 11-16	NO
Industrial Applicability (IA)	Claims 1-22	YES
	Claims NONE	NO

## 2. CITATIONS AND EXPLANATIONS

Claims 6-9 and 11-16 lack novelty under PCT Article 33(2) as being anticipated by the admission in the description on page 9, lines 24-27 that the combination of EDAC [1-ethyl-3-(3-dimethyl-aminopropyl)carbodiimide hydrochloride] and gycinamide is known as a combination of compounds that inhibits non-pepsin like acid protease

Claims 1-5, 10 and 17-22 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the type 4 prepilin peptidases nor methods of their use to design or screen inhibitors.

## ----- NEW CITATIONS -----

**INTERNATIONAL PRELIMINARY EXAMINATION REPORT**

International Application No.

PCT/US00/18775

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the questions whether the claims are fully supported by the description, are made:

The description is objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 5 because it fails to contain an adequate written description of any inhibitor of type 4 preprolin peptidases other than EDAC and glycaminide. The description is inadequate because: the structure of a chemical compound is not defined by a method of identification of the compound, nor can an undefined compound be used in a method of controlling bacteria.

Claims 6-8 and 9-16 are objected to as lacking clarity under PCT Rule 66.2(a)(v) because practice of the claimed invention is not adequately described in writing, as required under PCT Rule 5.1(a)(iii), for the reasons set forth in the immediately preceding paragraph.

Claims 1, 4, 6-7, 9, 15, and 17 are objected to under PCT Rule 66.2(a)(v) as lacking clarity under PCT Article 6 because the claims are indefinite for the following reason(s): TFP, EDAC and tcpJ are all abbreviations and are all without recitation of the full term after the first occurrence of the abbreviation.